Jazz Pharmaceuticals plc Selling, General and Administrative Expense
Jazz Pharmaceuticals plc (JAZZ) reported Selling, General and Administrative Expense of $389.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-03
- Jazz Pharmaceuticals plc selling, general and administrative expense for the quarter ending 2026-06-30 was $389.20M, a 8.59% increase year-over-year.
- Jazz Pharmaceuticals plc selling, general and administrative expense for the quarter ending 2026-03-31 was $352.70M, a 31.38% decline year-over-year.
- Jazz Pharmaceuticals plc selling, general and administrative expense for the quarter ending 2025-12-31 was $406.21M, a 10.00% increase year-over-year.
- Jazz Pharmaceuticals plc selling, general and administrative expense for the quarter ending 2025-09-30 was $530.65M, a 62.89% increase year-over-year.
- Jazz Pharmaceuticals plc selling, general and administrative expense for fiscal 2025 was $1.81B, a 30.61% increase from fiscal 2024.
- Jazz Pharmaceuticals plc selling, general and administrative expense for fiscal 2024 was $1.39B, a 3.14% increase from fiscal 2023.
- Jazz Pharmaceuticals plc selling, general and administrative expense for fiscal 2023 was $1.34B, a 5.21% decline from fiscal 2022.
- Jazz Pharmaceuticals plc selling, general and administrative expense for fiscal 2022 was $1.42B, a 2.39% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $389.20M 10-Q · filed 2026-08-03 | $741.90M 10-Q · filed 2026-08-03 | $1.15B derived: sum of 3 quarters · filed 2026-08-03 | $1.68B derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2026-03-31 | $352.70M 10-Q · filed 2026-05-05 | $758.91M derived: sum of 2 quarters · filed 2026-05-05 | $1.29B derived: sum of 3 quarters · filed 2026-05-05 | $1.65B derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-12-31 | $406.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $936.86M derived: sum of 2 quarters · filed 2026-02-24 | $1.30B derived: sum of 3 quarters · filed 2026-08-03 | $1.81B 10-K · filed 2026-02-24 | ||
| 2025-09-30 | $530.65M 10-Q · filed 2025-11-05 | $889.05M derived: sum of 2 quarters · filed 2026-08-03 | $1.40B 10-Q · filed 2025-11-05 | $1.77B derived: sum of 4 quarters · filed 2026-08-03 | ||
| 2025-06-30 | $358.40M 10-Q · filed 2026-08-03 | $358.40M 10-Q · filed 2025-08-06 | $872.40M 10-Q · filed 2026-08-03 | $872.41M 10-Q · filed 2025-08-06 | $1.24B derived: sum of 3 quarters · filed 2026-08-03 | $1.57B derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $514.00M 10-Q · filed 2026-05-05 | $514.01M 10-Q · filed 2025-05-07 | $883.29M derived: sum of 2 quarters · filed 2026-05-05 | $1.21B derived: sum of 3 quarters · filed 2026-05-05 | $1.55B derived: sum of 4 quarters · filed 2026-05-05 | |
| 2024-12-31 | $369.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $695.06M derived: sum of 2 quarters · filed 2026-02-24 | $1.03B derived: sum of 3 quarters · filed 2026-02-24 | $1.39B 10-K · filed 2026-02-24 | ||
| 2024-09-30 | $325.77M 10-Q · filed 2025-11-05 | $664.29M derived: sum of 2 quarters · filed 2025-11-05 | $1.02B 10-Q · filed 2025-11-05 | $1.41B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-06-30 | $338.52M 10-Q · filed 2025-08-06 | $690.24M 10-Q · filed 2025-08-06 | $1.09B derived: sum of 3 quarters · filed 2026-02-24 | $1.39B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2024-03-31 | $351.71M 10-Q · filed 2025-05-07 | $747.75M derived: sum of 2 quarters · filed 2026-02-24 | $1.06B derived: sum of 3 quarters · filed 2026-02-24 | $1.40B derived: sum of 4 quarters · filed 2026-02-24 | ||
| 2023-12-31 | $396.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $704.34M derived: sum of 2 quarters · filed 2026-02-24 | $1.05B derived: sum of 3 quarters · filed 2026-02-24 | $1.34B 10-K · filed 2026-02-24 | ||
| 2023-09-30 | $308.31M 10-Q · filed 2024-11-07 | $649.15M derived: sum of 2 quarters · filed 2024-11-07 | $947.07M 10-Q · filed 2024-11-07 | $1.33B derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $340.84M 10-Q · filed 2024-08-01 | $638.76M 10-Q · filed 2024-08-01 | $1.02B derived: sum of 3 quarters · filed 2025-02-26 | $1.38B derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $297.92M 10-Q · filed 2024-05-02 | $681.12M derived: sum of 2 quarters · filed 2025-02-26 | $1.04B derived: sum of 3 quarters · filed 2025-02-26 | $1.41B derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2022-12-31 | $383.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $741.68M derived: sum of 2 quarters · filed 2025-02-26 | $1.11B derived: sum of 3 quarters · filed 2025-02-26 | $1.42B 10-K · filed 2025-02-26 | ||
| 2022-09-30 | $358.48M 10-Q · filed 2023-11-08 | $724.95M derived: sum of 2 quarters · filed 2023-11-08 | $1.03B 10-Q · filed 2023-11-08 | $1.43B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-06-30 | $366.47M 10-Q · filed 2023-08-09 | $675.29M 10-Q · filed 2023-08-09 | $1.07B derived: sum of 3 quarters · filed 2024-02-28 | $1.44B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2022-03-31 | $308.81M 10-Q · filed 2023-05-10 | $707.27M derived: sum of 2 quarters · filed 2024-02-28 | $1.07B derived: sum of 3 quarters · filed 2024-02-28 | $1.50B derived: sum of 4 quarters · filed 2024-02-28 | ||
| 2021-12-31 | $398.46M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $762.14M derived: sum of 2 quarters · filed 2024-02-28 | $1.19B derived: sum of 3 quarters · filed 2024-02-28 | $1.45B 10-K · filed 2024-02-28 | ||
| 2021-09-30 | $363.68M 10-Q · filed 2022-11-09 | $792.71M derived: sum of 2 quarters · filed 2022-11-09 | $1.05B 10-Q · filed 2022-11-09 | $1.30B derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | $429.03M 10-Q · filed 2022-08-03 | $689.54M 10-Q · filed 2022-08-03 | $936.71M derived: sum of 3 quarters · filed 2023-03-01 | $1.14B derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | $260.51M 10-Q · filed 2022-05-04 | $507.68M derived: sum of 2 quarters · filed 2023-03-01 | $714.93M derived: sum of 3 quarters · filed 2023-03-01 | $906.34M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $247.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $454.43M derived: sum of 2 quarters · filed 2023-03-01 | $645.83M derived: sum of 3 quarters · filed 2023-03-01 | $854.23M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $207.25M 10-Q · filed 2021-11-09 | $398.66M derived: sum of 2 quarters · filed 2021-11-09 | $607.06M 10-Q · filed 2021-11-09 | $821.34M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-06-30 | $191.41M 10-Q · filed 2021-08-03 | $399.81M 10-Q · filed 2021-08-03 | $614.08M derived: sum of 3 quarters · filed 2022-03-01 | $792.79M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2020-03-31 | $208.40M 10-Q · filed 2021-05-04 | $422.68M derived: sum of 2 quarters · filed 2022-03-01 | $601.38M derived: sum of 3 quarters · filed 2022-03-01 | $777.39M derived: sum of 4 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $214.28M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $392.98M derived: sum of 2 quarters · filed 2022-03-01 | $569.00M derived: sum of 3 quarters · filed 2022-03-01 | $736.94M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $178.71M 10-Q · filed 2020-11-02 | $354.72M derived: sum of 2 quarters · filed 2020-11-02 | $522.67M 10-Q · filed 2020-11-02 | $684.53M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-06-30 | $176.01M 10-Q · filed 2020-08-04 | $343.96M 10-Q · filed 2020-08-04 | $505.83M derived: sum of 3 quarters · filed 2021-02-23 | $661.70M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2019-03-31 | $167.95M 10-Q · filed 2020-05-05 | $329.81M derived: sum of 2 quarters · filed 2021-02-23 | $485.69M derived: sum of 3 quarters · filed 2021-02-23 | $644.26M derived: sum of 4 quarters · filed 2021-02-23 | ||
| 2018-12-31 | $161.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-23 | $317.74M derived: sum of 2 quarters · filed 2021-02-23 | $476.32M derived: sum of 3 quarters · filed 2021-02-23 | $683.53M 10-K · filed 2021-02-23 | ||
| 2018-09-30 | $155.87M 10-Q · filed 2019-11-05 | $314.45M derived: sum of 2 quarters · filed 2019-11-05 | $521.66M 10-Q · filed 2019-11-05 | $664.72M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $158.58M 10-Q · filed 2019-08-06 | $365.79M 10-Q · filed 2019-08-06 | $508.84M derived: sum of 3 quarters · filed 2020-02-25 | $633.37M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | $207.21M 10-Q · filed 2019-05-07 | $350.26M derived: sum of 2 quarters · filed 2020-02-25 | $474.79M derived: sum of 3 quarters · filed 2020-02-25 | $607.11M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2017-12-31 | $143.05M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $267.57M derived: sum of 2 quarters · filed 2020-02-25 | $399.90M derived: sum of 3 quarters · filed 2020-02-25 | $544.16M 10-K · filed 2020-02-25 | ||
| 2017-09-30 | $124.52M 10-Q · filed 2018-11-06 | $256.85M derived: sum of 2 quarters · filed 2018-11-06 | $401.11M 10-Q · filed 2018-11-06 | $528.25M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-06-30 | $132.33M 10-Q · filed 2018-08-07 | $276.58M 10-Q · filed 2018-08-07 | $403.72M derived: sum of 3 quarters · filed 2019-02-26 | $528.09M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2017-03-31 | $144.25M 10-Q · filed 2018-05-08 | $271.40M derived: sum of 2 quarters · filed 2019-02-26 | $395.76M derived: sum of 3 quarters · filed 2019-02-26 | $518.38M derived: sum of 4 quarters · filed 2019-02-26 | ||
| 2016-12-31 | $127.14M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $251.51M derived: sum of 2 quarters · filed 2019-02-26 | $374.13M derived: sum of 3 quarters · filed 2019-02-26 | $502.89M 10-K · filed 2019-02-26 | ||
| 2016-09-30 | $124.37M 10-Q · filed 2017-11-07 | $246.99M derived: sum of 2 quarters · filed 2017-11-07 | $375.75M 10-Q · filed 2017-11-07 | $501.31M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-06-30 | $122.62M 10-Q · filed 2017-08-08 | $251.38M 10-Q · filed 2017-08-08 | $376.94M derived: sum of 3 quarters · filed 2018-02-27 | $480.98M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-03-31 | $128.76M 10-Q · filed 2017-05-09 | $254.32M derived: sum of 2 quarters · filed 2018-02-27 | $358.36M derived: sum of 3 quarters · filed 2018-02-27 | $465.50M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $125.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $229.60M derived: sum of 2 quarters · filed 2018-02-27 | $336.73M derived: sum of 3 quarters · filed 2018-02-27 | $449.12M 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $104.04M 10-Q · filed 2016-11-08 | $211.18M derived: sum of 2 quarters · filed 2016-11-08 | $323.56M 10-Q · filed 2016-11-08 | $429.26M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-06-30 | $107.13M 10-Q · filed 2016-08-09 | $219.52M 10-Q · filed 2016-08-09 | $325.21M derived: sum of 3 quarters · filed 2017-02-28 | $418.71M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-03-31 | $112.39M 10-Q · filed 2016-05-10 | $218.08M derived: sum of 2 quarters · filed 2017-02-28 | $311.58M derived: sum of 3 quarters · filed 2017-02-28 | $412.14M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $105.69M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $199.19M derived: sum of 2 quarters · filed 2017-02-28 | $299.75M derived: sum of 3 quarters · filed 2017-02-28 | $406.11M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $93.50M 10-Q · filed 2015-11-09 | $194.06M derived: sum of 2 quarters · filed 2015-11-09 | $300.42M 10-Q · filed 2015-11-09 | $381.72M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-06-30 | $100.56M 10-Q · filed 2015-08-05 | $206.92M 10-Q · filed 2015-08-05 | $288.22M derived: sum of 3 quarters · filed 2016-02-23 | $363.19M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2014-03-31 | $106.36M 10-Q · filed 2015-05-07 | $187.66M derived: sum of 2 quarters · filed 2016-02-23 | $262.63M derived: sum of 3 quarters · filed 2016-02-23 | $340.14M derived: sum of 4 quarters · filed 2016-02-23 | ||
| 2013-12-31 | $81.30M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-23 | $156.27M derived: sum of 2 quarters · filed 2016-02-23 | $233.78M derived: sum of 3 quarters · filed 2016-02-23 | $304.30M 10-K · filed 2016-02-23 | ||
| 2013-09-30 | $74.97M 10-Q · filed 2014-11-04 | $152.48M derived: sum of 2 quarters · filed 2014-11-04 | $223.00M 10-Q · filed 2014-11-04 | $284.38M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2013-06-30 | $77.51M 10-Q · filed 2014-08-05 | $148.03M 10-Q · filed 2014-08-05 | $209.41M derived: sum of 3 quarters · filed 2015-02-24 | $270.33M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2013-03-31 | $70.53M 10-Q · filed 2014-05-08 | $131.91M derived: sum of 2 quarters · filed 2015-02-24 | $192.83M derived: sum of 3 quarters · filed 2015-02-24 | $250.05M derived: sum of 4 quarters · filed 2015-02-24 | ||
| 2012-12-31 | $61.38M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $122.30M derived: sum of 2 quarters · filed 2015-02-24 | $179.53M derived: sum of 3 quarters · filed 2015-02-24 | $223.88M 10-K · filed 2015-02-24 | ||
| 2012-09-30 | $60.92M 10-Q · filed 2013-11-05 | $118.15M derived: sum of 2 quarters · filed 2013-11-05 | $162.50M 10-Q · filed 2013-11-05 | $198.89M derived: sum of 4 quarters · filed 2014-02-25 | ||
| 2012-06-30 | $57.22M 10-Q · filed 2013-08-06 | $60.64M 10-Q · filed 2012-08-07 | $101.58M 10-Q · filed 2013-08-06 | $107.64M 10-Q · filed 2012-08-07 | $137.96M derived: sum of 3 quarters · filed 2014-02-25 | $168.51M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $44.36M 10-Q · filed 2013-05-07 | $47.00M 10-Q · filed 2012-05-08 | $80.74M derived: sum of 2 quarters · filed 2014-02-25 | $111.29M derived: sum of 3 quarters · filed 2014-02-25 | $133.38M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2011-12-31 | $36.38M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $66.93M derived: sum of 2 quarters · filed 2014-02-25 | $89.03M derived: sum of 3 quarters · filed 2014-02-25 | $108.94M 10-K · filed 2014-02-25 | ||
| 2011-09-30 | $30.55M 10-Q · filed 2012-11-09 | $52.64M derived: sum of 2 quarters · filed 2012-11-09 | $72.55M 10-Q · filed 2012-11-09 | $89.62M derived: sum of 4 quarters · filed 2013-02-26 | ||
| 2011-06-30 | $22.09M 10-Q · filed 2012-08-07 | $42.01M 10-Q · filed 2012-08-07 | $59.08M derived: sum of 3 quarters · filed 2013-02-26 | $77.11M derived: sum of 4 quarters · filed 2013-02-26 | ||
| 2011-03-31 | $19.91M 10-Q · filed 2012-05-08 | $36.98M derived: sum of 2 quarters · filed 2013-02-26 | $55.02M derived: sum of 3 quarters · filed 2013-02-26 | $72.12M derived: sum of 4 quarters · filed 2013-02-26 | ||
| 2010-12-31 | $17.07M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $35.11M derived: sum of 2 quarters · filed 2013-02-26 | $52.21M derived: sum of 3 quarters · filed 2013-02-26 | $69.00M 10-K · filed 2013-02-26 | ||
| 2010-09-30 | $18.04M 10-Q · filed 2011-11-08 | $35.14M derived: sum of 2 quarters · filed 2011-11-08 | $51.93M 10-Q · filed 2011-11-08 | |||
| 2010-06-30 | $17.10M 10-Q · filed 2011-08-03 | $33.89M 10-Q · filed 2011-08-03 | ||||
| 2009-12-31 | $58.65M 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |